Officer/Director Mayukh Sukhatme Files Intent to Sell $17M in Shares Near 52-Week High
ROIV has more than doubled off its 52-week low of $10.705 on elevated volume (2.1× avg).
Summary
An Officer and Director at Roivant Sciences has filed an intent to sell $17 million in shares, adding to recent insider sales as the stock approaches its 52-week high.
Key Events · Ownership and Investor Activity · ROIV
-
Officer/Director Intent to Sell
Mayukh Sukhatme, an Officer and Director, filed a Form 144 to sell 500,000 common shares, valued at approximately $17.04 million.
-
Follows Recent Disposition
This proposed sale comes immediately after Sukhatme sold 500,000 shares for $17.05 million on June 25, 2026, indicating a pattern of dispositions.
-
Near 52-Week High
The intent to sell occurs as Roivant Sciences' stock is trading near its 52-week high, potentially signaling profit-taking by an insider.
-
Part of Broader Insider Distribution
This filing contributes to a net insider distribution of over $22 million in open-market sales over the last 90 days.
Analysis · ROIV · Life Sciences
Mayukh Sukhatme, an Officer and Director, has filed a Form 144 indicating intent to sell approximately $17 million worth of common shares. This proposed sale follows a similar disposition yesterday and contributes to a broader pattern of insider distribution, occurring while the stock trades near its 52-week high. This suggests insiders are taking profits after recent positive financial news.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1963 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.14%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ROIV was trading at $34.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.5B. The 52-week trading range was $10.71 to $34.68. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.